Vivanza Biosciences (BOM:530057) Total Equity: ₹44 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:530057 Vivanza Biosciences Ltd BOM:530057
58 GF Score
Price ₹1.83
GF Value ₹26.45
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Vivanza Biosciences Total Equity?

Vivanza Biosciences BOM:530057 +1.67% 58 Total Equity is ₹44 Mil as of Mar. 2026. GuruFocus rates BOM:530057 with a GF Score™ of 58/100 and a GF Value™ of ₹26.45 (Possible Value Trap). The stock has 3 warning signs investors should review.

Vivanza Biosciences's total equity for the quarter that ended in Mar. 2026 was ₹44 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Vivanza Biosciences Total Equity Historical Data

* Premium members only.

The historical data trend for Vivanza Biosciences's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vivanza Biosciences Total Equity Chart

Vivanza Biosciences Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 34.93 40.91 46.38 39.64 43.59

Vivanza Biosciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 39.64 0.00 46.14 0.00 43.59
BOM:530057
58GF Score
Vivanza Biosciences Ltd BOM:530057
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vivanza Biosciences Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Vivanza Biosciences's Total Equity for the fiscal year that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=220.874-177.289
=44

Vivanza Biosciences's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=220.874-177.289
=44

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of ₹44 Mil mean?
Vivanza Biosciences (BOM:530057) has a Total Equity of ₹44 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for Vivanza Biosciences and its competitors.
Is Vivanza Biosciences' Total Equity too high?
Vivanza Biosciences' current Total Equity is ₹44 Mil. Overall, Vivanza Biosciences has a GF Score™ of 58/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Vivanza Biosciences' Total Equity compare to ZTS and UTHR?
Vivanza Biosciences' Total Equity of ₹44 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Drug Manufacturers company?
A good Total Equity depends on the Drug Manufacturers industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Vivanza Biosciences and its competitors. Vivanza Biosciences's current Total Equity is ₹44 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vivanza Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Vivanza Biosciences (BOM:530057) is currently considered Possible Value Trap. The stock's GF Value™ is ₹26.45, compared to a current price of ₹1.83 — trading 93.1% below its estimated fair value. The current Total Equity is ₹44 Mil. Vivanza Biosciences' overall GF Score™ is 58/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Vivanza Biosciences (BOM:530057), the current Total Equity is ₹44 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vivanza Biosciences (BOM:530057) Overvalued in 2026?

Based on GuruFocus' analysis, Vivanza Biosciences stock appears to be undervalued. The current stock price of ₹1.83 is trading 93.1% below its estimated GF Value™ of ₹26.45. GuruFocus considers Vivanza Biosciences to be Possible Value Trap.

Key valuation signals for BOM:530057:

  • Total Equity: ₹44 Mil
  • GF Value™: ₹26.45 vs. price of ₹1.83 (93.1% below fair value)
  • GF Score™: 58/100 with 3 warning signs

No single metric tells the full story. See the BOM:530057 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Vivanza Biosciences Business Description

Address S.G. Highway, 403/TF, Sarthik II, Opposite Rajpath Club, Bodakdev, Ahmedabad, GJ, IND, 380054
Vivanza Biosciences Ltd is a pharmaceutical company. Its core focus areas include research and development, manufacturing, and the distribution of a wide range of pharma and pharmaceutical products. The company's product portfolio includes Medical examination gloves, Injections, Veterinary feeds, and others.
58GF Score

Get the complete analysis for BOM:530057

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1.83
Price
₹26.45
GF Value